potently inhibits tumor growth in human cancer xenograft models including SCLC models while trigged significantly less platelet killing. Method: Three clinical studies are ongoing, including two Phase I doseescalation studies in United States(NCT03080311) and Australia (ACTRN12616001597482), and a Phase I/II study in China (CTR20170976). APG-1252 dose ranging from 10 mg to 400 mg, will be administered via intravenous infusion for 30 minutes, twice weekly, once on Days 1, 4, 8, 11, 15, 18 and 22 in a 28-day-cycle, until disease progression or unacceptable toxicities. Tumor assessment per RECIST is performed every 2 cycles. The primary objective is to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), preliminary efficacy and MTD/RP2D of single-agent APG-1252 in metastatic solid tumors including SCLC. Results: As of Aug 31, 2018, 35 patients (including 17 pts with SCLC) have been treated in 6 dose level of APG-1252.The current dose level being explored is 240 mg. Here is a preliminary pool analysis of three studies. APG-1252 was well-tolerated across all dose levels tested. The MTD has not yet been reached. Most adverse events (AE) were mild or moderate in severity, no drug-related AEs leading to drug discontinuation. Only one patient experienced a drug-related serious adverse event (SAE), consisting of a decrease in platelet count was transient and recovered with 72 hours without any treatment or dose interruption. Of 10 SCLC patients who have had at least one posttreatment tumor assessment, one US patient with metastatic SCLC has confirmed partial response (PR) at a dose level of 40mg. After 6 cycles of APG-1252, the target lesion decreased by 44%. The response is durable and this patient has been receiving treatment for 16 cycles. Three patients from China at 80mg dose level had stable disease (SD) after 2 treatment cycles, one of them was confirmed SD. PK analyses indicate that AUC and Cmax increase dose proportionally over 10-160 mg range, AUC and Cmax are comparable between US and Chinese subjects at same dose level. Conclusion: APG-1252 was well-tolerated and the MTD has not been reached. Majority of AEs are Grade 1 or 2. No drug-related AE lead to treatment discontinuation. Preliminary anticancer effect had been observed in some SCLC patients. ; 19 del group, n¼77). Baseline characteristics were similar among groups with the exception of age. The median PFS (by IRC) were 9.2 months (95%CI 8.3, 10.7), 12.9 (10.1, 15.8), and 12.5 (9.2, 13.9) for 21 L858R-RD, 21 L858R-HD, and 19 del group, respectively, for modified intent-to-treat population (p¼0.0848); and 8.8 months (8.2, 10.6), 12.6 (9.6, 14.3), and 12.2 (9.2, 13.6) for per-protocol set (p¼0.0445). The ORR were 47.7%, 73.3%, and 75.3% for 21 L858R-RD, 21 L858R-HD, and 19 del group, respectively (p¼0.0007). Patients in high-dose group experienced significantly higher incidence of AEs than routine-dose groups (21 L858R-RD vs 21 L858R-HD vs 19 del: 54.7% vs 81.1% vs 66.2%, p¼0.0007) but the incidences of grade 3/4 AE were similar among the groups (4.7% vs 5.6% vs 5.2%, p¼0.9632). Conclusion: High-dose icotinib prolonged PFS and improved ORR in NSCLC patients harboring L858R mutation with tolerable toxicity. For this group of patients, high-dose icotinib can be the new standard of care. Keywords: Phase 2, High-dose icotinib, Non-small-cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR) mutation OA14 Phase 2 Study: Tepotinib + Gefitinib in MET+/ Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer activation; dual MET/EGFR inhibition may have potential in EGFR TKI-resistant NSCLC. Tepotinib is a potent, selective MET TKI. We report randomized phase 2 data from a phase 1b/2 signal detection trial of tepotinib+gefitinib vs chemotherapy (pemetrexed + cisplatin/carboplatin) in patients with MET+/EGFR+T790M-NSCLC (NCT01982955). Method: Asian patients with advanced MET+ (IHC2+, IHC3+, gene amplification) NSCLC, acquired resistance to 1 st -line EGFR TKI and ECOG performance status 0e1 were eligible. Tumors had an EGFR-activating mutation (T790M-). Patients received tepotinib (500mg)+gefitinib (250mg) once-daily. Primary endpoint: progression-free survival (PFS by investigator). Secondary endpoints: safety, antitumor activity, pharmacokinetics. Results: Due to low recruitment, enrolment was halted after 55 patients were randomized to tepotinib+gefitinib (n¼31) or chemotherapy (n¼24): males (n¼23), median age 60.4 (range 42e82) years. There was a numeric trend favoring tepotinib+gefitinib on PFS (hazard ratio [HR]: 0.71 [0.36, 1.39] ), driven by IHC3+ (HR: 0.35 [0.17, 0.74] ) and 0.57] ) patients (Table) confirming these as predictive biomarkers as shown by phase 1b data. All patients had treatment-related (TR) treatment-emergent adverse events (TEAEs). In the tepotinib+gefitinib vs chemotherapy arms, respectively, 9.7 vs 4.3% had TEAEs leading to permanent discontinuation, 3.2 vs 0% had TEAEs leading to death (none were TRTEAEs), 16.1 vs 30.4% had serious TRTEAEs, 51.6 vs 52.2% had grade 3 TRTEAEs, 12.9 vs 8.7% had a TRTEAE of special interest (lipase/amylase increase grade 3). Conclusion: Tepotinib+gefiti-nib shows promising antitumor activity in patients with MET protein overexpression (IHC3+) and gene amplification EGFR-mutant NSCLC and was generally well-tolerated. This positive signal warrants further exploration in this patient population. Keywords: EGFRI TKI-resistant non-small cell lung cancer, Gefitinib, Tepotinib, Antitumor activity 
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